Uric acid and dementia: a pathogenic factor or marker of cognitive health?
pdf

Keywords

hyperuricemia, uric acid, cognitive impairment, dementia, Parkinson’s disease, Alzheimer’s disease, neurodegenerative diseases, risk factor.

How to Cite

Golovach , I., & Yehudina , Y. (2019). Uric acid and dementia: a pathogenic factor or marker of cognitive health?. The Journal of Neuroscience, 7(2), 43-53. Retrieved from https://neuroscience.com.ua/index.php/journal/article/view/6

Abstract

In epidemiological studies, hyperuricemia was recognized as an independent risk factor for the development of cardiovascular diseases. However, uric acid (UA) can have a positive effect due to its antioxidant properties, which may be particularly relevant in the context of the development of neurodegenerative diseases. In this paper, we critically revise recent data on the relationship between serum UA levels and cognitive functions in the elderly, with emphasis on etiological factors for cognitive impairment, such as Alzheimer’s disease, Parkinson’s disease and vascular dementia, and on the relationship between UA, dementia and diet. Despite the high heterogeneity in existing studies, due to the different characteristics of the studied populations and heterogeneous methods for assessing cognitive dysfunction, it can be concluded that serum UA can modulate cognitive function in various ways according to the dementia etiology. Current research does show that UA can have a neuroprotective effect in Alzheimer’s and Parkinson’s disease, and hypouricemia is a risk factor for faster progression of neurodegenerative diseases and to be a possible marker of malnutrition in these patients. However, high levels of serum UA adversely affect the course of the disease in vascular dementia. Further studies are needed to clarify the physiopathological role of UA in various types of dementia and its clinical and prognostic significance.

pdf

References

1. Anderson G., Maes M. Neurodegeneration in Parkinson’s disease: Interactions of oxidative stress, tryptophan catabolites and depression with mitochondria and
sirtuins // Mol. Neurobiol. — 2014. — Vol. 49. — P. 771- 783. doi: 10.1007/s12035-013-8554-z.
2. Annanmaki T., Pohja M., Parviainen T., et al. Uric acid and cognition in Parkinson’s disease: A follow-up study // Parkinsonism Relat. Disord. — 2011. — Vol. 17. — P. 333-337.
3. Beberashvili I., Sinuani I., Azar A., et al. Serum uric acid as a clinically useful nutritional marker and predictor of outcome in maintenance hemodialysis patients // Nutrition. — 2015. — Vol. 31. — P. 138-147. doi: 10.1016/j. nut.2014.06.012.
4. Bell S., Kolobova I., Crapper L., Ernst C. Lesch- Nyhan Syndrome: Models, Theories, and Therapies // Mol. Syndromol. — 2016. — Vol. 7. — P. 302-311.
doi:10.1159/000449296.
5. Bowman G.L., Shannon J., Frei B., et al. Uric acid as a CNS antioxidant // J. Alzheimers Dis. — 2010. — Vol. 19. — P. 1331-1336. doi: 10.3233/JAD‑2010-1330.
6. Cederholm T., Nouvenne, A., Ticinesi, A., et al. The role of malnutrition in older persons with mobility limitations // Curr. Pharm. Des. — 2014. — Vol. 20. —
P. 3173-3177.
7. Chang C.C., Wu C.H., Liu L.K. Association between serum uric acid and cardiovascular risk in nonhypertensive and nondiabetic individuals: The Taiwan I-Lan Longitudinal Aging Study // Sci. Rep. — 2018. — Vol. 8. — P. 5234 doi: 10.1038/s41598-018-22997-0.
8. Chen X., Guo X., Huang R., et al. Serum uric acid levels in patients with Alzheimer’s disease: A meta-analysis. // PLoS ONE. — 2014. — Vol. 9. — P. 94084 doi: 10.1371/ journal.pone.0094084.
9. Dalbeth N., Merriman T.R., Stamp L.K. Gout // Lancet. — 2016. — Vol. 388. — P. 2039-2052. — https://doi.org/10.1016/S0140-6736(16)00346-9
10. Desideri G., Gentile R., Antonosante A., et al. Uric Acid Amplifies A-Amyloid Effects Involved in the Cognitive Dysfunction/Dementia: Evidences From an Experimental Model In Vitro // J. Cell. Physiol. — 2017. — Vol. 232. — P. 1069-1078. doi: 10.1002/jcp.25509.
11. Du N., Xu D., Hou X., et al. Inverse Association Between Serum Uric Acid Levels and Alzheimer’s Disease Risk // Mol. Neurobiol. — 2016. — Vol. 53. — P. 2594-2599.
12. Euser S.M., Hofman A., Westendorp R.G., Breteler M.M. Serum uric acid and cognitive function and dementia // Brain. — 2009. — Vol. 132. — P. 377-382.
doi: 10.1093/brain/awn316.
13. Euser S.M., Irizarry M.C., Raman, R. et al. Plasma urate and progression of mild cognitive impairment // Neurodegener. Dis. — 2009. — Vol. 6. — P. 23-28. doi:
10.1159/000170883.
14. Gao X., O’Reilly É.J., Schwarzschild M.A., Ascherio A. Prospective study of plasma urate and risk of Parkinson disease in men and women // Neurology. — 2016. — Vol. 86. — P. 520-526. doi: 10.1212/WNL.0000000000002351.
15. Hong J.Y., Lan T.Y., Tang G.J., et al. Gout and the risk of dementia: a nationwide population-based cohort study // Arthritis Res. Ther. — 2015. — Vol. 17. — P. 139.